title: Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.
abstract: Pancreatic neuroendocrine tumors (pNETs) differ in their clinical behavior, presentation and prognosis based on their initial histological features and disease stage. While small resectable tumors can be treated surgically, metastatic and locally advanced disease carries a significant mortality and treatment options have been limited in terms of their efficacy. Streptozocin-based regimens were the only agents available before but recent advances have improved the armamentarium to treat pNETs. Newer chemotherapeutic agents such as temozolomide, somatostatin analogs and targeted therapies including everolimus and sunitinib are now available to treat these tumors. Several combination regimens with targeted therapies and newer agents such as pazopanib are being developed and tested in ongoing trials.
authors.affiliation: Tufts University School of Medicine, Tufts Medical Center, Boston, MA, USA.
authors.forename: Jaya
authors.initials: J
authors.lastname: Sharma
authors.forename: Marvin
authors.initials: M
authors.lastname: Duque
authors.forename: M Wasif
authors.initials: MW
authors.lastname: Saif
keywords: drug therapy; everolimus; neuroendocrine tumors; pancreatic neoplasms; sunitinib; vascular endothelial growth factors